

Biomaterial development for oral and maxillofacial bone regeneration

Lindsay S. Karfeld-Sulzer, Franz E. Weber

*Oral Biotechnology and Bioengineering, Department of Cranio-Maxillofacial and Oral Surgery,
University Hospital Zurich, Zurich, Switzerland*

Abstract (J Korean Assoc Oral Maxillofac Surg 2012;38:264-70)

Many oral and maxillofacial bone defects are not self-healing. Guided bone regeneration (GBR), which uses a barrier membrane to prevent the soft tissues from invading the defect to enable slower-growing bone cells to penetrate the area, was developed as a therapy in the 1980s. Although there has been some success with GBR in some clinical situations, better treatments are needed. This review discusses the concept of GBR focusing on bioactive membranes that incorporate osteoconductive materials, growth factors and cells for improved oral and maxillofacial bone regeneration.

Key words: Bone, Guided bone regeneration, Barrier membrane, Bone substitutes, Drug delivery, Stem cells

[paper submitted 2012. 8. 30 / accepted 2012. 9. 9]

I. Introduction

Facial trauma, bone resection due to cancer, periodontal disease, and bone atrophy after tooth extraction may leave non-self-healing oral and maxillofacial bone defects¹. Although there is an inherent self-repair potential, a non-union remains for bone gaps greater than 25 mm or even only 500 μ m, depending on the location, vascularization, and the mechanics². The presence of infection or inflammation is another determining factor for bone regeneration capability at a given site. For the alveolar bone in particular, periodontitis, advanced periodontal disease that affects around 15% of adult humans, induces the destruction of the alveolar bone around teeth and can cause them to fall out^{3,4}. Without the mechanical stimulus from teeth, alveolar bone naturally further degrades^{4,5}. Interventions with tooth implants are additionally complicated since sufficient quantity and quality of the alveolar bone must be present to stabilize the implant⁶. Peri-implantitis, infection and inflammation around tooth implants, can have the same detrimental effects on the

alveolar bone that periodontitis has on natural teeth.

As discussed by Mikos et al.⁷, there are some unique challenging aspects of tissue regeneration in oral and maxillofacial tissues. The irregular architecture and necessary precision of positioning the biomaterial replacements suggest injectable or moldable substitutes. Implants need sufficient mechanical properties and appropriate resorption rates that coordinate with tissue ingrowth. Moreover, the environment of the oral cavity with its flora presents additional complications for alveolar bone engineering.

Despite these challenges, guided bone regeneration (GBR) was developed and has served as a treatment since the 1980s for restoring osseous maxillofacial tissues^{8,9}. An excellent overview on this subject was provided by Buser¹⁰. Through the use of a barrier membrane, this therapeutic strategy physically excludes ineffective soft tissue cells to allow osteoprogenitor cells to populate the area. Since its initial conception, the GBR membranes have progressed from non-resorbable to resorbable to bioactive occlusive materials. GBR has been shown to reliably close critical size periodontal defects and can even support neo-osteogenesis, bone growth extending past the original boundaries¹¹. Although there has been success with GBR in various clinical situations, others, particularly alveolar ridge augmentation combined with implant placement, require further research to improve outcomes¹¹. Thus, research on advanced materials, growth factor incorporation, and the inclusion of cells is ongoing to improve GBR for oral and maxillofacial bone regeneration.

Franz E. Weber

Oral Biotechnology and Bioengineering, Department of Cranio-Maxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstrasse 24, 8091 Zurich, Switzerland

TEL: +41-44-255-5055 FAX: +41-44-255-4179

E-mail: franz.weber@zsm.uzh.ch

©This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

II. Guided Bone Regeneration

1. Concept and requirements

GBR gained traction as a therapy in the 1980s, but in 1957 there was already an initial report of space creation with plastic cages for bone regeneration in femoral defects in dogs¹². Other studies followed, including those focusing on the craniofacial area^{13,14}, but the mechanism of action was initially hypothesized to be the protection of the blood clot. In the early 1980s, the guided tissue regeneration principle was established, explaining that a specific tissue can be regenerated when cells with the restorative ability for that tissue type are able to occupy the wound space^{9,15}. Through space maintenance and the preclusion of faster growing cells from the gingival connective tissue and oral mucosal epithelium, osteogenic cells are allowed to infiltrate and form bone^{8,9,15-17}.

By enabling new bone formation, GBR may obviate the use of autologous bone grafts. Although an excellent source, the use of autogenous tissue is not desirable due to the pain and morbidity associated with the graft harboring site^{4,18}. To function properly, GBR membranes must meet certain requirements, including cell exclusion, space creation, scaffolding for progenitor cell in-growth, biocompatibility, host tissue integration, and clinical manageability^{1,11,17}.

2. Non-resorbable and resorbable membranes

The first generation of barrier membranes was non-resorbable, with expanded polytetrafluoroethylene (ePTFE) (Teflon; Gore, Flagstaff, AZ, USA) membranes becoming the most frequently used^{1,8,11}. With its high stability, non-immunogenicity, and reliably successful results, ePTFE membranes have been considered a gold standard for bone regeneration^{11,19}, despite the fact that ePTFE-membrane exposure to the oral cavity always resulted in a failure of the treatment.

Even with the favorable outcomes using non-resorbable ePTFE, the strong disadvantage of requiring a second surgery to remove the material encouraged the development of a second generation of GBR with degradable barrier membranes. Along with the morbidity associated with a second surgical procedure for non-resorbable membrane removal, there is a risk of tissue damage and disturbed healing¹⁹. Additionally, there are some post-surgical complications of membrane exposure with non-biodegradable membranes that lead to a high incidence of infection that

can decrease bone regeneration^{20,21}. Besides avoiding the second surgery, resorbable membranes are also advantageous because of improved soft tissue healing and lower bacterial contamination risk due to decreased exposure from the degrading membrane¹⁹. In addition to the requirements stated previously, there are also further properties that these barrier membranes must fulfill: biocompatible degradation products that don't interfere with bone regeneration, appropriate degradation profile to synchronize with new tissue growth, and sufficient persistent mechanical and physical properties to perform the barrier function and allow *in vivo* use³.

Amongst the most common bioresorbable membranes are synthetic polyesters (poly(lactic acid), poly(glycolic acid), and poly(caprolactone) and their copolymers)²²⁻²⁵ and tissue-derived collagen^{21,26-29}. Polyester membranes display biocompatibility and possess a high degree of customization, with degradation rates and mechanical properties that can be adjusted based on polymer composition and concentration^{30,31}. As a natural component of the extracellular matrix, collagen is biocompatible and cell adhesive. Although collagen isn't inherently mechanically stable, it can be modified through various means of crosslinking³. Poly(ethylene glycol) (PEG) is also known as a biodegradable and biocompatible polymer. Since many oral and maxillofacial defects require precise shapes, an injectable material is desirable, such as a PEG-based *in situ* forming gel for GBR that demonstrated effectiveness in a clinical trial³²⁻³⁴.

In addition to the type of material, the physical form also plays a role in determining a material's properties, which can affect degradation rates and tissue integration. Porosity is one of the most important characteristics. With some materials, such as poly(lactide-co-glycolide), the porosity can be imposed by using porogens that form the pores and then are removed in a subsequent processing step³⁵. Electrospinning is a manufacturing technique that creates elongated fibers with a degree of control over properties including fiber length, width, and orientation and overall porosity³. Researchers have explored these techniques for improving GBR membranes.

Although the existing bioresorbable membranes fulfill many requirements, most of them cannot maintain adequate space to act as a barrier membrane over an extended period of time^{5,19}. However, in combination with a bone substitute material, these composite membranes have shown success²⁴.

III. Bioactive Membranes

In addition to providing mechanical support to resorbable

GBR membranes, the inclusion of bone substitute materials can render a membrane bioactive. Current research aims to develop a third generation of GBR membranes that are not only occlusive and degradable, but also contain bioactivity to biologically stimulate osteoprogenitor cells for enhanced bone growth. Using tissue engineering principles, advanced materials with the incorporation of bioactive molecules and cells are being explored for the development of the next generation of membranes. Instead of simply maintaining a space for osteoprogenitor ingrowth, the critical aspects of the natural environment are being recapitulated.

1. Bone graft materials

Effective bone graft materials can biologically stimulate bone growth through either osteoconduction by allowing cell growth through a scaffolding mechanism or osteoinduction by recruiting osteoprogenitors into the defect space⁴. Although cancellous autogenous bone grafts act as an osteoconductive material, the associated morbidity of the graft site restricts its use. Other natural sources include both allografts and xenografts, which are processed to reduce immunogenicity³⁶. Demineralized bovine bone matrix retains type-1 collagen, non-collagenous proteins as well as a small amount of osteoinductive growth factors³⁷. One of the most common commercially used products is deproteinized bovine bone matrix, Bio-Oss (Geistlich Biomaterials, Wolhusen, Switzerland), which is stripped of all organic elements by pyrolysis, a high temperature sintering, leaving hydroxyapatite (HA) as the main component³⁸. Unfortunately, high temperature sintering also affects HA and alters it from a biological HA to a more synthetic one³⁹. Despite positive outcomes of naturally-derived materials, there are still concerns regarding disease transmission and immunogenicity⁴.

Synthetic graft materials supply various formulations of calcium phosphate without the limitations of the animal-derived products. Bone is composed of a majority of calcium phosphate and these synthetic substitutes are known to have biologically active surface chemistry for osseointegration⁴⁰. Additionally, these biodegradable, inorganic materials have a crystallographic structure similar to bone and controllable porosity that is important for mimicking bone, making them effective substitutes^{41,42}. HA has been utilized as granules^{42,43}, incorporated as nanoparticles³, or as a coating⁴⁴. Tricalcium phosphate (TCP), which resorbs faster than HA, is another commonly used inorganic bone substitute^{41,45}. Bioactive

glass is another inorganic bone graft material that displays osteoconduction and an ability to bond with bone through chemical linkages^{46,47}.

2. Growth factors

Membranes and graft materials can act as a barrier to fibrous tissue ingrowth and a scaffold to support bone and some even provide some osteoinductive activity, but a further critical role of biomaterials in improving oral and maxillofacial bone regeneration is delivering bioactive molecules. Growth factors are signaling proteins that regulate cellular growth, proliferation, and differentiation. Enamel matrix derivative and platelet rich plasma are both biologically-derived products that contain multiple growth factors and have demonstrated enhanced healing in periodontal tissues even though the mechanism of action is not understood^{3,48,49}. Platelet rich plasma is comprised of various autologous growth factors that have individually been identified to enhance bone regeneration, including platelet-derived growth factor⁵⁰, fibroblast growth factor⁵¹, and insulin-like growth factor⁵², but its positive effect on regeneration processes appears to be restricted to soft tissue healing^{49,53}.

The class of bone morphogenetic proteins (BMPs), first identified to generate extraskelatal bone formation in bone extracts in 1965⁵⁴, have now been extensively studied and shown to be critical for the induction of bone⁵⁵. The class of BMPs consists of 15 variants, with BMP-2, BMP-4, BMP-7, and BMP-12 shown to be particularly effective in bone regeneration⁵⁶. BMP-2 and BMP-7 have been recombinantly produced for commercial use⁴⁵. BMP-2 has shown impressive potential to regenerate bone in animal studies and the clinic, including in oral applications⁵⁷. GBR in conjunction with BMP-2 delivery by a bone substitute material has been shown to be an effective strategy in humans as well⁵⁸. However, milligram doses that are orders of magnitude higher than normal physiological levels are required⁵⁹. An enhancer of BMP-2, such as N-methyl pyrrolidone (NMP), can possibly avoid the high cost and possible side effects and safety concerns of the large dose⁶⁰. In a rabbit calvarial model, NMP enhanced bone regeneration over a polylactide membrane alone, emphasizing the importance of the bioactivity⁶¹.

Besides enhancers, controlled release of growth factors can increase their efficiency. In fact, acting as a vehicle for local delivery of growth factors and protecting them from degradation and inactivation are major roles of biomaterials.

A slow, controlled release BMP-2 delivery system has been shown to induce and sustain bone formation⁶². Many of the same materials used as bone grafts have also been explored as delivery systems: collagen⁶³, calcium phosphates⁶⁴, and polyesters like polycaprolactone⁶⁵.

Growth factors can non-covalently bind or covalently attach to the carrier⁶⁶. Non-covalent growth factor delivery systems can function through adsorption (e.g., collagen sponge⁶³ and deproteinized bovine bone matrix³⁸), ion complexation with charged polymers (e.g., poly-L-ornithine and poly-L-arginine complexes⁶⁷) or physical entrapment (e.g., polyesters⁶⁸ and PEG³⁸). The materials that physically incorporate growth factors can take various forms from liposomes⁶⁹ to nanoparticles⁷⁰ to hydrogels⁷¹. In contrast to these modes of delivery, covalent systems retain growth factors at the site of action until cleaved off or the carrier is degraded, extending the residence time⁶⁶. Additionally, immobilization enables spatial growth factor delivery, limits side effects by constraining the growth factors to the site of action, and mimics physiological matrix-bound situations⁷². Growth factors can be covalently tethered to a material directly^{73,74} or through a linker^{75,76}. Another strategy is genetically engineering fusion growth factors that include an attachment site outside the active protein sequence. BMP-2 was engineered to contain amino acid domains that enable both enzymatic covalent attachment to and release from fibrin-based substances, creating a system that mimics physiological binding and liberation⁷⁷. Although it is possible that the growth factor may lose some activity through all of these covalent immobilization methods, this loss may be mitigated by the higher retention and other advantages.

3. Cells

In addition to allowing the delivery of bioactive molecules, biomaterials are also critical for enabling cell-based therapies. To encourage proliferation and differentiation, cells require an artificial extracellular matrix, which can be supplied through an appropriately designed biomaterial³⁶. Including a cell source can further encourage oral and maxillofacial bone growth through direct tissue growth and bone repair as well as growth factor secretion from the cells⁷⁸. Although this area has only been actively pursued relatively recently, due to advancements in biological cell research, there are some promising studies.

Mesenchymal stem cells (MSCs), multipotent adult stem cells that can be harvested from mesenchymal tissues such as

bone marrow, have been suggested as a cell source for tissue engineering⁵⁶. Since they are easily attained and expanded, bone marrow MSCs (BMSCs) are the most commonly explored MSCs³⁶. A number of studies have demonstrated alveolar bone regeneration with BMSCs⁷⁹⁻⁸¹. A study also showed the positive effect of combining stem cells with growth factor release through BMP-2 expressing BMSCs⁸².

In addition to BMSCs, there are several other cell types that are being explored for oral and maxillofacial bone tissue engineering. Umbilical cord MSCs are another easily obtainable reservoir of stem cells and initial studies show promising results for bone regeneration with this source⁸³⁻⁸⁶. Adipose-derived stem cells are other extraoral and non-craniofacial cells that are easily accessible and were successfully used to regenerate bone^{87,88}. The periodontal ligament and dental pulp are both sources of stem cells in the oral cavity that have been isolated and characterized^{56,89}. Stem cells from both of these tissues have demonstrated bone regeneration capabilities⁹⁰⁻⁹². However, these cells are more difficult to harvest³⁶.

With all of these stem cells sources, the biomaterial that supports them is a critical aspect for facilitating bone regeneration. Many of the same materials that have been developed as bone graft materials and bioactive molecule delivery vehicles have been explored as cell scaffolds. HA⁹³, collagen⁹⁴, fibrin⁸⁷, and poly(lactide-co-glycolide)⁹⁵ as well as composites such as HA/TCP⁹⁶, chitosan-gelatin⁷⁹, and calcium phosphate cement-chitosan-polyglactin⁸⁶ are amongst these scaffolds.

IV. Conclusion

The field of bone regeneration for oral and maxillofacial tissues has progressed dramatically from the first non-resorbable GBR membranes to bioactive materials. Guided by tissue engineering principles, there is a large amount of current research on designing membranes consisting of bioactive materials that can deliver growth factors and cells. Future improvements will require appropriate combinations of materials, growth factors and cells that permit temporal and spatial growth factor release, suitable degradation profiles that both allow tissue ingrowth and maintain sufficient occlusivity, and positive mimicking of the extracellular matrix to support and encourage cell proliferation and differentiation. Composite materials, multi-layered constructs, and varying physical forms are amongst the possible strategies in biomaterial development for this

ongoing body of research.

References

- Hitti RA, Kerns DG. Guided bone regeneration in the oral cavity: a review. *The Open Pathology Journal* 2011;5:33-45.
- Johner R. Dependence of bone healing on defect size. *Helv Chir Acta* 1972;39:409-11.
- Bottino MC, Thomas V, Schmidt G, Vohra YK, Chu TM, Kowolik MJ, et al. Recent advances in the development of GTR/GBR membranes for periodontal regeneration--a materials perspective. *Dent Mater* 2012;28:703-21.
- Hughes FJ, Ghuman M, Talal A. Periodontal regeneration: a challenge for the tissue engineer? *Proc Inst Mech Eng H* 2010;224:1345-58.
- Hämmerle CH, Karring T. Guided bone regeneration at oral implant sites. *Periodontol* 2000 1998;17:151-75.
- Araujo MG, Lindhe J. Dimensional ridge alterations following tooth extraction. An experimental study in the dog. *J Clin Periodontol* 2005;32:212-8.
- Mikos AG, Herring SW, Ochareon P, Elisseeff J, Lu HH, Kandel R, et al. Engineering complex tissues. *Tissue Eng* 2006;12:3307-39.
- Dahlin C, Linde A, Gottlow J, Nyman S. Healing of bone defects by guided tissue regeneration. *Plast Reconstr Surg* 1988;81:672-6.
- Nyman S, Lindhe J, Karring T, Rylander H. New attachment following surgical treatment of human periodontal disease. *J Clin Periodontol* 1982;9:290-6.
- Buser D. 20 years of guided bone regeneration in implant dentistry. 2nd ed. Berlin: Quintessence; 2009.
- Retzeppi M, Donos N. Guided Bone Regeneration: biological principle and therapeutic applications. *Clin Oral Implants Res* 2010;21:567-76.
- Murray G, Holden R, Roschlau W. Experimental and clinical study of new growth of bone in a cavity. *Am J Surg* 1957;93:385-7.
- Kahnberg KE. Restoration of mandibular jaw defects in the rabbit by subperiosteally implanted Teflon mantle leaf. *Int J Oral Surg* 1979;8:449-56.
- Melcher AH. Role of the periosteum in repair of wounds of the parietal bone of the rat. *Arch Oral Biol* 1969;14:1101-9.
- Karring T, Nyman S, Lindhe J. Healing following implantation of periodontitis affected roots into bone tissue. *J Clin Periodontol* 1980;7:96-105.
- Gottlow J, Nyman S, Karring T, Lindhe J. New attachment formation as the result of controlled tissue regeneration. *J Clin Periodontol* 1984;11:494-503.
- Karring T, Nyman S, Gottlow J, Laurell L. Development of the biological concept of guided tissue regeneration--animal and human studies. *Periodontol* 2000 1993;1:26-35.
- McAllister BS, Haghighat K. Bone augmentation techniques. *J Periodontol* 2007;78:377-96.
- Hammerle CH, Jung RE. Bone augmentation by means of barrier membranes. *Periodontol* 2000 2003;33:36-53.
- Murphy KG. Postoperative healing complications associated with Gore-Tex Periodontal Material. Part I. Incidence and characterization. *Int J Periodontics Restorative Dent* 1995;15:363-75.
- Wang HL, Carroll MJ. Guided bone regeneration using bone grafts and collagen membranes. *Quintessence Int* 2001;32:504-15.
- Gentile P, Chiono V, Tonda-Turo C, Ferreira AM, Ciardelli G. Polymeric membranes for guided bone regeneration. *Biotechnol J* 2011;6:1187-97.
- Geurs NC, Korostoff JM, Vassilopoulos PJ, Kang TH, Jeffcoat M, Kellar R, et al. Clinical and histologic assessment of lateral alveolar ridge augmentation using a synthetic long-term bioabsorbable membrane and an allograft. *J Periodontol* 2008;79:1133-40.
- Sculean A, Nikolidakis D, Schwarz F. Regeneration of periodontal tissues: combinations of barrier membranes and grafting materials--biological foundation and preclinical evidence: a systematic review. *J Clin Periodontol* 2008;35(8 Suppl):106-16.
- Milella E, Barra G, Ramires PA, Leo G, Aversa P, Romito A. Poly(L-lactide)acid/alginate composite membranes for guided tissue regeneration. *J Biomed Mater Res* 2001;57:248-57.
- Tal H, Kozlovsky A, Artzi Z, Nemcovsky CE, Moses O. Cross-linked and non-cross-linked collagen barrier membranes disintegrate following surgical exposure to the oral environment: a histological study in the cat. *Clin Oral Implants Res* 2008;19:760-6.
- Parodi R, Carusi G, Santarelli G, Nanni F. Implant placement in large edentulous ridges expanded by GBR using a bioresorbable collagen membrane. *Int J Periodontics Restorative Dent* 1998;18:266-75.
- Colangelo P, Piattelli A, Barrucci S, Trisi P, Formisano G, Caiazza S. Bone regeneration guided by resorbable collagen membranes in rabbits: a pilot study. *Implant Dent* 1993;2:101-5.
- Coïc M, Placet V, Jacquet E, Meyer C. Mechanical properties of collagen membranes used in guided bone regeneration: a comparative study of three models. *Rev Stomatol Chir Maxillofac* 2010;111:286-90.
- Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. *Polymers (Basel)* 2011;3:1377-97.
- Vert M. Aliphatic polyesters: great degradable polymers that cannot do everything. *Biomacromolecules* 2005;6:538-46.
- Jung RE, Halg GA, Thoma DS, Hammerle CH. A randomized, controlled clinical trial to evaluate a new membrane for guided bone regeneration around dental implants. *Clin Oral Implants Res* 2009;20:162-8.
- Jung RE, Zwahlen R, Weber FE, Molenberg A, van Lenthe GH, Hammerle CH. Evaluation of an in situ formed synthetic hydrogel as a biodegradable membrane for guided bone regeneration. *Clin Oral Implants Res* 2006;17:426-33.
- Wechsler S, Fehr D, Molenberg A, Raeber G, Schense JC, Weber FE. A novel, tissue occlusive poly(ethylene glycol) hydrogel material. *J Biomed Mater Res A* 2008;85:285-92.
- Amini AR, Adams DJ, Laurencin CT, Nukavarapu SP. Optimally porous and biomechanically compatible scaffolds for large-area bone regeneration. *Tissue Eng Part A* 2012;18:1376-88.
- Chen FM, Jin Y. Periodontal tissue engineering and regeneration: current approaches and expanding opportunities. *Tissue Eng Part B Rev* 2010;16:219-55.
- Calori GM, Mazza E, Colombo M, Ripamonti C. The use of bone-graft substitutes in large bone defects: any specific needs? *Injury* 2011;42(Suppl 2):S56-63.
- Hanseler P, Jung UW, Jung RE, Choi KH, Cho KS, Hammerle CH, et al. Analysis of hydrolyzable polyethylene glycol hydrogels and deproteinized bone mineral as delivery systems for glycosylated and non-glycosylated bone morphogenetic protein-2. *Acta Biomater* 2012;8:116-23.
- Henkel KO, Gerber T, Lenz S, Gundlach KK, Bienengraber V. Macroscopical, histological, and morphometric studies of porous bone-replacement materials in minipigs 8 months after implantation. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006;102:606-13.
- Palarie V, Bicer C, Lehmann KM, Zahalka M, Draenert FG, Kammerer PW. Early outcome of an implant system with a resorbable adhesive calcium-phosphate coating--a prospective clinical study in partially dentate patients. *Clin Oral Investig* 2012;16:1039-48.
- Hannink G, Arts JJ. Bioresorbability, porosity and mechanical strength of bone substitutes: what is optimal for bone regeneration? *Injury* 2011;42(Suppl 2):S22-5.
- Kruse A, Jung RE, Nicholls F, Zwahlen RA, Hammerle CH, Weber FE. Bone regeneration in the presence of a synthetic

- hydroxyapatite/silica oxide-based and a xenogenic hydroxyapatite-based bone substitute material. *Clin Oral Implants Res* 2011;22:506-11.
43. Qu Y, Wang P, Man Y, Li Y, Zuo Y, Li J. Preliminary biocompatible evaluation of nano-hydroxyapatite/polyamide 66 composite porous membrane. *Int J Nanomedicine* 2010;5:429-35.
 44. Kamitakahara M, Ohtsuki C, Miyazaki T. Coating of bone-like apatite for development of bioactive materials for bone reconstruction. *Biomed Mater* 2007;2:R17-23.
 45. Darby I. Periodontal materials. *Aust Dent J* 2011;56(Suppl 1):107-18.
 46. San Miguel B, Kriauciunas R, Tosatti S, Ehrbar M, Ghayor C, Textor M, et al. Enhanced osteoblastic activity and bone regeneration using surface-modified porous bioactive glass scaffolds. *J Biomed Mater Res A* 2010;94:1023-33.
 47. Mota J, Yu N, Caridade SG, Luz GM, Gomes ME, Reis RL, et al. Chitosan/bioactive glass nanoparticle composite membranes for periodontal regeneration. *Acta Biomater* 2012;8:4173-80.
 48. Grandin HM, Gemperli AC, Dard M. Enamel matrix derivative: a review of cellular effects in vitro and a model of molecular arrangement and functioning. *Tissue Eng Part B Rev* 2012;18:181-202.
 49. Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: literature review. *Tissue Eng Part B Rev* 2008;14:249-58.
 50. Thoma DS, Jung RE, Hanseler P, Hammerle CH, Cochran DL, Weber FE. Impact of recombinant platelet-derived growth factor BB on bone regeneration: a study in rabbits. *Int J Periodontics Restorative Dent* 2012;32:195-202.
 51. Hong KS, Kim EC, Bang SH, Chung CH, Lee YI, Hyun JK, et al. Bone regeneration by bioactive hybrid membrane containing FGF2 within rat calvarium. *J Biomed Mater Res A* 2010;94:1187-94.
 52. Kang H, Sung J, Jung HM, Woo KM, Hong SD, Roh S. Insulin-like growth factor 2 promotes osteogenic cell differentiation in the parthenogenetic murine embryonic stem cells. *Tissue Eng Part A* 2012;18:331-41.
 53. Jung RE, Schmoekel HG, Zwahlen R, Kokovic V, Hammerle CH, Weber FE. Platelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2. *Clin Oral Implants Res* 2005;16:676-82.
 54. Urist MR. Bone: formation by autoinduction. *Science* 1965;150:893-9.
 55. Ripamonti U, Reddi AH. Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. *Crit Rev Oral Biol Med* 1997;8:154-63.
 56. Elangovan S, Srinivasan S, Ayilavarapu S. Novel regenerative strategies to enhance periodontal therapy outcome. *Expert Opin Biol Ther* 2009;9:399-410.
 57. Wikesjo UM, Qahash M, Huang YH, Xiropaidis A, Polimeni G, Susin C. Bone morphogenetic proteins for periodontal and alveolar indications; biological observations-clinical implications. *Orthod Craniofac Res* 2009;12:263-70.
 58. Jung RE, Glauser R, Scharer P, Hammerle CH, Sailer HF, Weber FE. Effect of rhBMP-2 on guided bone regeneration in humans. *Clin Oral Implants Res* 2003;14:556-68.
 59. Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. *Bone* 2006;39:61-71.
 60. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. *Spine J* 2011;11:471-91.
 61. Miguel BS, Ghayor C, Ehrbar M, Jung RE, Zwahlen RA, Hortschansky P, et al. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. *Tissue Eng Part A* 2009;15:2955-63.
 62. Hunziker EB, Enggist L, Kuffer A, Buser D, Liu Y. Osseointegration: the slow delivery of BMP-2 enhances osteoinductivity. *Bone* 2012;51:98-106.
 63. Herford AS, Boyne PJ. Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2). *J Oral Maxillofac Surg* 2008;66:616-24.
 64. Jung RE, Weber FE, Thoma DS, Ehrbar M, Cochran DL, Hammerle CH. Bone morphogenetic protein-2 enhances bone formation when delivered by a synthetic matrix containing hydroxyapatite/tricalciumphosphate. *Clin Oral Implants Res* 2008;19:188-95.
 65. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. *Biomaterials* 2011;32:5241-51.
 66. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone repair. *Eur J Pharm Biopharm* 2004;58:197-208.
 67. Abbah SA, Liu J, Lam RW, Goh JC, Wong HK. In vivo bioactivity of rhBMP-2 delivered with novel polyelectrolyte complexation shells assembled on an alginate microbead core template. *J Control Release* 2012;162:364-72.
 68. Zellin G, Linde A. Importance of delivery systems for growth-stimulatory factors in combination with osteopromotive membranes. An experimental study using rhBMP-2 in rat mandibular defects. *J Biomed Mater Res* 1997;35:181-90.
 69. Matsuo T, Sugita T, Kubo T, Yasunaga Y, Ochi M, Murakami T. Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model. *J Biomed Mater Res A* 2003;66:747-54.
 70. Machado R, Bessa PC, Reis RL, Rodriguez-Cabello JC, Casal M. Elastin-based nanoparticles for delivery of bone morphogenetic proteins. *Methods Mol Biol* 2012;906:353-63.
 71. Bulpitt P, Aeschlimann D. New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. *J Biomed Mater Res* 1999;47:152-69.
 72. Masters KS. Covalent growth factor immobilization strategies for tissue repair and regeneration. *Macromol Biosci* 2011;11:1149-63.
 73. Park J, Bauer S, Pittrof A, Killian MS, Schmuki P, von der Mark K. Synergistic control of mesenchymal stem cell differentiation by nanoscale surface geometry and immobilized growth factors on TiO₂ nanotubes. *Small* 2012;8:98-107.
 74. Yamachika E, Tsujigiwa H, Shirasu N, Ueno T, Sakata Y, Fukunaga J, et al. Immobilized recombinant human bone morphogenetic protein-2 enhances the phosphorylation of receptor-activated Smads. *J Biomed Mater Res A* 2009;88:599-607.
 75. Park YJ, Kim KH, Lee JY, Ku Y, Lee SJ, Min BM, et al. Immobilization of bone morphogenetic protein-2 on a nanofibrous chitosan membrane for enhanced guided bone regeneration. *Biotechnol Appl Biochem* 2006;43:17-24.
 76. Zhang H, Migneco F, Lin CY, Hollister SJ. Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells. *Tissue Eng Part A* 2010;16:3441-8.
 77. Schmoekel HG, Weber FE, Schense JC, Gratz KW, Schawaldler P, Hubbell JA. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. *Biotechnol Bioeng* 2005;89:253-62.
 78. Rios HF, Lin Z, Oh B, Park CH, Giannobile WV. Cell- and gene-based therapeutic strategies for periodontal regenerative medicine. *J Periodontol* 2011;82:1223-37.
 79. Miranda SC, Silva GA, Mendes RM, Abreu FA, Caliari MV, Alves JB, et al. Mesenchymal stem cells associated with porous chitosan-gelatin scaffold: A potential strategy for alveolar bone regeneration. *J Biomed Mater Res A* 2012;100:2775-86.
 80. Hasegawa N, Kawaguchi H, Hirachi A, Takeda K, Mizuno N, Nishimura M, et al. Behavior of transplanted bone marrow-derived mesenchymal stem cells in periodontal defects. *J Periodontol*

- 2006;77:1003-7.
81. Li H, Yan F, Lei L, Li Y, Xiao Y. Application of autologous cryo-preserved bone marrow mesenchymal stem cells for periodontal regeneration in dogs. *Cells Tissues Organs* 2009;190:94-101.
 82. Chung VH, Chen AY, Kwan CC, Chen PK, Chang SC. Mandibular alveolar bony defect repair using bone morphogenetic protein 2-expressing autologous mesenchymal stem cells. *J Craniofac Surg* 2011;22:450-4.
 83. Thein-Han W, Liu J, Xu HH. Calcium phosphate cement with biofunctional agents and stem cell seeding for dental and craniofacial bone repair. *Dent Mater* 2012;28:1059-70.
 84. Wang B, Huang S, Pan L, Jia S. Enhancement of bone formation by genetically engineered human umbilical cord-derived mesenchymal stem cells expressing osterix. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012 Jul 19. [Epub ahead of print]
 85. Wen Y, Jiang B, Cui J, Li G, Yu M, Wang F, et al. Superior osteogenic capacity of different mesenchymal stem cells for bone tissue engineering. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012 Jul 26. [Epub ahead of print]
 86. Zhao L, Burguera EF, Xu HH, Amin N, Ryou H, Arola DD. Fatigue and human umbilical cord stem cell seeding characteristics of calcium phosphate-chitosan-biodegradable fiber scaffolds. *Biomaterials* 2010;31:840-7.
 87. Lendeckel S, Jodicke A, Christophis P, Heidinger K, Wolff J, Fraser JK, et al. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. *J Craniomaxillofac Surg* 2004;32:370-3.
 88. Mesimaki K, Lindroos B, Tornwall J, Mauno J, Lindqvist C, Kontio R, et al. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. *Int J Oral Maxillofac Surg* 2009;38:201-9.
 89. Liu H, Gronthos S, Shi S. Dental pulp stem cells. *Methods Enzymol* 2006;419:99-113.
 90. Liu HC, E LL, Wang DS, Su F, Wu X, Shi ZP, et al. Reconstruction of alveolar bone defects using bone morphogenetic protein 2 mediated rabbit dental pulp stem cells seeded on nano-hydroxyapatite/collagen/poly(L-lactide). *Tissue Eng Part A* 2011;17:2417-33.
 91. Liu Y, Zheng Y, Ding G, Fang D, Zhang C, Bartold PM, et al. Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine. *Stem Cells* 2008;26:1065-73.
 92. Park JY, Jeon SH, Choung PH. Efficacy of periodontal stem cell transplantation in the treatment of advanced periodontitis. *Cell Transplant* 2011;20:271-85.
 93. Noshi T, Yoshikawa T, Ikeuchi M, Dohi Y, Ohgushi H, Horiuchi K, et al. Enhancement of the in vivo osteogenic potential of marrow/hydroxyapatite composites by bovine bone morphogenetic protein. *J Biomed Mater Res* 2000;52:621-30.
 94. Niu LN, Jiao K, Qi YP, Nikonov S, Yiu CK, Arola DD, et al. Intrafibrillar silicification of collagen scaffolds for sustained release of stem cell homing chemokine in hard tissue regeneration. *FASEB J* 2012 Aug 2. [Epub ahead of print]
 95. Partridge K, Yang X, Clarke NM, Okubo Y, Bessho K, Sebald W, et al. Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. *Biochem Biophys Res Commun* 2002;292:144-52.
 96. Vahabi S, Amirizadeh N, Shokrgozar MA, Mofeed R, Mashhadi A, Aghaloo M, et al. A comparison between the efficacy of Bio-Oss, hydroxyapatite tricalcium phosphate and combination of mesenchymal stem cells in inducing bone regeneration. *Chang Gung Med J* 2012;35:28-37.